YA II PN, LTD acquires JUPITER NEUROSCIENCES, INC. for USD 1,860,000 (2025)

Deal facts

Buyer: YA II PN, LTD
Target: JUPITER NEUROSCIENCES, INC.
Deal value: USD 1,860,000
Announced: 23 December 2025
Status: Completed
Sector: Healthcare
Country: United States
Consideration: shares, loan-note

Sources

SEC_EDGAR_8K

What we know

Weekly digest

Join Exit Mode Insider

Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.

Join Exit Mode Insider, £12/mo

Deal timeline

1 update

23 Dec 2025CompletedClosed
YA II PN, LTD completes acquisition of JUPITER NEUROSCIENCES, INC.
Item 1.01 Entry Into a Material Definitive Agreement. Standby Equity Purchase Agreement Reference is made to the Current Report on Form 8-K filed by Jupiter Neurosciences Inc. (the “Company”) with the Securities and Exchange Commission (the “SEC”) on October 27, 2025 (as amended by the Current Report on Form 8-K/A filed by the Company with th e SEC on November 20, 2025, collectively, the “Signing
Source

OpinionExit Mode editorial

We see a completed minority stake acquisition in the healthcare sector where YA II PN, LTD has acquired a position in Jupiter Neurosciences, Inc. The deal, announced on 23 December 2025, values the transaction at 1.86 million USD. This structure is notable because the buyer is based in the Cayman Islands while the target operates in the United States. The consideration comprises both shares and a loan note, which creates a hybrid capital stack rather than a simple cash exit. This is a common mechanism when buyers want to preserve cash upfront while deferring part of the payment or aligning future value with performance.

For the SME founder reading this, the use of a loan note alongside shares introduces specific commercial risks that differ from a standard all-cash deal. A loan note creates a creditor relationship, meaning the buyer owes you a fixed sum at a future date, often with interest, but this obligation sits alongside the equity stake. If the target company faces liquidity issues post-close, the repayment of that note could become contingent on the business generating sufficient cash flow. You must scrutinise the covenants attached to that loan note to understand if you have security or if you are effectively subordinated to other debt. Furthermore, cross-border structures involving Cayman entities often trigger complex change-of-control covenants in existing contracts, which can restrict your ability to operate or refinance without explicit consent from the new shareholder.

The regulatory context here is less about antitrust thresholds given the minority nature of the stake, but the healthcare sector always demands careful attention to compliance. The mix of shares and debt in the consideration suggests the buyer is testing the waters or managing capital efficiency. It is a signal that the buyer values the technology or team but wants to limit immediate capital outlay. This approach shifts some risk back to the seller, who now holds a piece of paper representing a future payment rather than immediate liquidity.

Your immediate action this week is to request the full terms of the loan note agreement from your legal counsel to verify the repayment schedule and any events of default that could accelerate the debt.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2025 deals More minority stake deals More from YA II PN, LTD All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

15 December 2025CompletedHealthcare

AI Technology Group Inc. to acquire AVM Biotechnology Inc.

AI Technology Group Inc. and AVM Biotechnology Inc. entered the Exit Mode archive.

Buyer: AI Technology Group Inc.
Target: AVM Biotechnology Inc.
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

15 December 2025CompletedHealthcare

XOMA Royalty Corporation to acquire Generation Bio Co.

XOMA Royalty Corporation and Generation Bio Co. entered the Exit Mode archive.

Buyer: XOMA Royalty Corporation
Target: Generation Bio Co.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

21 November 2025CompletedHealthcare

Lixte Biotechnology Holdings, Inc. to acquire Liora Technologies Europe Ltd.

Lixte Biotechnology Holdings, Inc. and Liora Technologies Europe Ltd. entered the Exit Mode archive.

Buyer: Lixte Biotechnology Holdings, Inc.
Target: Liora Technologies Europe Ltd.
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United Kingdom deals

12 November 2025In reviewHealthcare

WARBURG PINCUS to acquire SEBIA

WARBURG PINCUS has agreed to acquire SEBIA in a transaction announced on 12 November 2025. The deal involves a company operating across multiple industrial sectors, incl…

Buyer: WARBURG PINCUS
Target: SEBIA
Deal value: Not disclosed
Deal type: unknown

Read deal Healthcare deals unknown deals In review deals

11 November 2025In reviewHealthcare

CAPVEST to acquire STADA GROUP

CAPVEST has agreed to acquire STADA GROUP in a transaction announced on 11 November 2025. The deal involves a company operating within the pharmaceutical manufacturing s…

Buyer: CAPVEST
Target: STADA GROUP
Deal value: Not disclosed
Deal type: unknown

Read deal Healthcare deals unknown deals In review deals

Buyer history

YA II PN, LTD

See every published Exit Mode archive entry where this buyer appears.

View buyer profile

Methodology

How this page is built

Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.

Back to the archive

YA II PN, LTD to acquire JUPITER NEUROSCIENCES, INC.